We performed radioimmunoprecipitation assays in which iodinated prepara (4, 6 and references cited therein). One subpopulation reacts with homologous and heterologous viruses and has been designated cross-reactive (CR), and the other reacts with only homologous virus and has been termed strain specific (SS). This observation has led to the conclusion that the hemagglutinin (HA) possesses two types of antigenic deteminants. However, other studies in which the photometric antibody concentration unit method was used suggested that CR and SS antibodies have the same specificity but differ in avidity (1) .
Previous reports from our laboratory have described the development of direct and competition radioimmunoprecipitation (RIP) assays in which iodinated preparations of purified HAs are used as test antigens (10, 11) . Since such procedures are ideally suited for assessing the specificity and avidity of antigen-antibody reactions, we used them to characterize SS antihemagglutinin antibody (AHAB) raised to an H3N2 virus variant in adults by immunization with an inactivated whole virus vaccine. In addition, we also present data on the relative efficiency of this type of antibody population for inhibiting viral hemagglutination.
(Some of the results were presented at the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Mass., 1979.) MATERIALS AND METHODS Viral antigens. Allantoic fluid harvests of H3N2 virus variants that were representative of A/Hong Kong/68 (A/HK/68), A/England/72 (A/Eng/72), A/Port Chalmers/73 (A/PC/73), and A/Victoria/75 (A/Vic/75) were purified by rate zonal centrifugation through discontinuous sucrose gradients.
HA proteins derived from strains that were representative of A/HK/68 and A/PCM3 were purified by electrophoresis on cellulose acetate strips, as previously described (5) .
Antisera and adsorption procedure. We obtained sera from volunteers known to have developed SS A/ PC/73 antibodies by the standard viral adsorption and HI techniques after they were inoculated intramuscularly with 0.5 ml of licensed whole virus vaccine that contained 700 chick cell agglutination units of a strain representative of A/PC/73 and 300 chick cell agglutina- lodination of HA and RIP procedures. Purified HAs were radiolabeled with 1251 by the chloramine T technique, as previously described (10) . The specific activities of the antigens used in this study ranged from 6.8 to 9.7 ,uCi/,ug of protein. In all preparations, more than 95% of the radioactivity was precipitable by 10% trichloroacetic acid, and more than 85% was precipitable by specific antiserum.
Serum AHAB levels were determined by direct RIP assays, as previously described (10) . Briefly, dilutions of an antiserum were reacted with iodinated HA (approximately 10,000 cpm). A dilution of carrier serum (free of AHAB) was added to each assay tube to maintain a constant immunoglobulin G concentration. After incubation, goat anti-human immunoglobulin G in equivalence with carrier serum was added to separate immune complexes. The highest dilution of an antiserum that precipitated 35% of the antigen was taken as the endpoint, and the titer was expressed as the reciprocal of that dilution.
For competition RIP assays, a purified whole virus preparation was diluted serially in RIP buffer containing 0.3% Triton X-100. The detergent was added to disrupt virus, thus freeing the HA, and to prevent aggregation during the assay (11) . Dilutions of competing antigen were incubated with dilutions of antiserum before iodinated antigen was added. Then we used the procedure described above for the direct RIP assay to complete the assay.
Other procedures. Serum AHAB titers were determined by the standard HI test in microtiter plates (9) .
Each test was performed with antigenic hybrids possessing the relevant (H3) HA and the neuraminidase of A/equine/1/Prague/56 (H7N7) virus. The antibody titer was expressed as the reciprocal of the highest serum dilution that completely inhibited viral hemagglutination.
Protein determinations were performed as described by Lowry et al. (7), using bovine serum albumin (Pentex) as the standard. c GMT, Geometric mean titer. A titer of 100 was assigned to sera with undetectable antibody (titer, <200). levels of serum antibodies to both variants. We used competition RIP assays to assess the SS AHAB response. The concentration of unlabeled A/HK/68 HA required to inhibit the binding of CR antibody to t25I-labeled A/PC/73 HA was determined with post-vaccination sera from volunteers 5 and 6; these sera contained the highest levels of antibody to A/HK/68 HA. The AHAB titration curves determined by direct RIP assays for volunteers 5 and 6 are shown in Fig.  1A and B. For volunteer 5, the post-immunization antibody titers to A/HK/68 and A/PC/73 were 27,940 and 62,244 respectively; for volunteer 6, these values were 31,931 and 9,603, respectively. We then tested the antisera for the ability to precipitate 125I-labeled A/HK/68 HA and 125I-labeled A/PC/73 HA in the presence of increasing concentrations of unlabeled A/HK/68 antigens ( Fig. 1C and D) to each dilution of prevaccination serum, reactivity with both A/HK/68 HA and A/PC/73 HA was completely inhibited for all volunteers, indicating that the antibodies that were reactive with A/PC/73 HA at that time were all CR (data not shown). However, these studies on postvaccination sera indicated that each volunteer had developed SS antibodies to the AIPC/73 HA present in the vaccine (Table 2) .
RESULTS
Since the RIP assays measured antigen-binding capacity, the titers provided estimates of the SS antibody responses in proportion to the total A/PC/73 HA response. The proportion of SS antibody ranged from 8% (volunteer 6) to 48% (volunteer 8); the mean was 20% of the total antibody to A/PC/73 HA. The SS AHAB titers to A/PC/73 obtained in competition RIP assays were comparable to the titers observed with A/ HK/68 adsorbed sera (data not shown). Figure 2 shows a comparison of the A/PC/73 antibody levels as determined by RIP and HI assays. The RIP antibody titers ranged from 19-to 153-fold higher than the corresponding HI titers in postvaccination sera; after adsorption the RIP titers were 15-to 108-fold higher than the HI titers. Moreover, a comparison of these ratios indicated that they were relatively constant for each antiserum; that is, adsorption of the sera resulted in proportional decreases in the antibody titers as determined by both procedures. This finding suggested that the efficiency of SS antibodies for inhibiting viral hemagglutination was not markedly different than the efficiency of the total antibody population.
We also used competition RIP assays to determine whether the SS AHAB to A/PC/73 that remained after adsorption of postvaccination sera with A/HK/68 exhibited cross-reactivity with other variants of the H3N2 subtype (Table  3) . _ . . Our data do not agree with the data reported by Drescher and Verhagen (1). Using chicken antiserum, these investigators concluded that SS and CR antibodies have the same specificity but differ in avidity. Since the same influenza H3N2 variants were used in their study and our study, antigenic differences cannot explain this apparent discrepancy. However, the repertoire of Bcell clones that are capable of producing antibodies to HAs in different animal species may explain the contrasting results.
Recent reports have suggested that the proportions of SS antibodies in hyperimmunized rabbit antisera depend on the degree of the antigenic relationship between the adsorbing and immunizing viruses (3, 8) . The wide range of avidities shown by human SS antibodies in heterologous reactions is consistent with these observations. However, our findings suggest that both specificity and avidity play roles in the adsorption characteristics of the antibody population. 
